Primary Care Patient Interest in Multi-Cancer Early Detection for Cancer Screening

Author:

Myers Ronald E.1,Hallman Mie H.1,Shimada Ayako2ORCID,DiCarlo Melissa1,Davis Kaitlyn3ORCID,Leach William T.3,Jackson Hattie1ORCID,Indictor Amanda1,Chambers Christopher V.3

Affiliation:

1. Division of Population Science, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA

2. Division of Biostatistics, Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA

3. Department of Family and Community Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA

Abstract

Multi-cancer early detection (MCED) tests are being developed, but little is known about patient receptivity to their use for cancer screening. The current study assessed patient interest in such testing. Our team conducted a prospective, observational study among primary care patients in a large, urban health system. They were asked to complete a telephone survey that briefly described a new blood test in development to identify multiple types of cancer, but was not currently recommended or covered by insurance. The survey included items to assess respondent background characteristics, perceptions about MCED testing, and interest in having such an MCED test. We also used multivariable analyses to identify factors associated with patient interest in test use. In 2023, we surveyed 159 (32%) of 500 identified patients. Among respondents, 125 (79%) reported a high level of interest in having an MCED test. Interest was not associated with personal background characteristics, but was positively associated with the following expectations: testing would be recommended for cancer screening, be convenient, and be effective in finding early-stage disease (OR = 11.70, 95% CI: 4.02, 34.04, p < 0.001). Research is needed to assess patient interest and actual uptake when detailed information on testing is presented in routine care.

Funder

Thomas Jefferson University’s Sidney Kimmel Cancer Center

Exact Sciences Corporation, Madison, WI, USA

Publisher

MDPI AG

Subject

Medicine (miscellaneous)

Reference30 articles.

1. Lokshin, A., Bast, R.C., and Rodland, K. (2021). Circulating Cancer Biomarkers. Cancers, 13.

2. Nadauld, L.D., McDonnell, C.H., Beer, T.M., Liu, M.C., Klein, E.A., Hudnut, A., Whittington, R.A., Taylor, B., Oxnard, G.R., and Lipson, J. (2021). The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. Cancers, 13.

3. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set;Klein;Ann. Oncol.,2021

4. National Cancer Institute Division of Cancer Prevention (2023, October 24). Multi-Cancer Detection (MCD) Research, Available online: https://prevention.cancer.gov/major-programs/multi-cancer-detection-mcd-research.

5. United States Preventive Services Taskforce (2023, October 24). Recommendation: Lung Cancer: Screening. Available online: https://www.uspreventiveservicestaskforce.org/uspstf/index.php/recommendation/lung-cancer-screening#bootstrap-panel--13.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3